Dr Reddys Laboratories RDY
NYSE RDY
$14.90 +0.38 (+2.62%)
At close: Nov 6, 2026 · 4:00 PM EST

Dr Reddys Laboratories (RDY) Liabilities from Discontinued Operations (2018)

Updated

Dr Reddys Laboratories' Liabilities from Discontinued Operations came in at $1.06 million for fiscal Q2 2019 (quarter ended Sep 30, 2018).

Analysis

Dr Reddys Laboratories (RDY) Liabilities from Discontinued Operations (2018) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,224.11 Bn 1,197.72 Bn 20.46 Bn
2 Johnson & Johnson 665.34 Bn 585.20 Bn 17.30 Bn
3 AbbVie 515.72 Bn 483.73 Bn 13.12 Bn
4 Merck 362.64 Bn 325.58 Bn 13.19 Bn
5 Novartis Ag 315.51 Bn 288.75 Bn -
6 Astrazeneca 289.26 Bn 263.15 Bn 13.26 Bn
7 Amgen 249.20 Bn 200.85 Bn 7.58 Bn
8 Gilead Sciences 207.48 Bn 182.59 Bn 6.73 Bn
9 Pfizer 167.49 Bn 114.85 Bn 12.56 Bn
10 Dr Reddys Laboratories 12.40 Bn 11.74 Bn 472.93 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2018 1.06 Mn
API Access

Dr Reddys Laboratories Liabilities from Discontinued Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-from-discontinued-operations&ticker=RDY&period=max&api_key=YOUR_API_KEY